Pharmaceuticals News and Research

RSS

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Teenagers use medicines frequently without receiving targeted information about risks and benefits

A large proportion of teenagers regularly and frequently take some form of medication without receiving targeted information about the risks and benefits, according to a review of current research, to be presented at the annual congress of the International Pharmaceutical Federation.

5 Sep 2011

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

An international team of researchers has found a group of mutations involved in T-cell acute lymphoblastic leukemia (T-ALL), and showed that a group of certain drugs, already in clinical use to treat other diseases, can eliminate the cells carrying these mutations.

5 Sep 2011

Berlin to market wide range of Acino Pharma's current and future products in Thailand

Berlin Pharmaceutical Industry Co., Ltd. and Acino Pharma AG signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company's current and future products in Thailand.

5 Sep 2011

Study describes new class of anti-diabetic compound that targets unique molecular switch

In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch.

5 Sep 2011

Inhibiting the ability of immune cells to use fatty acids slows MS progression

In a paper published today in the journal Scientific Reports, a pair of researchers at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences report that inhibiting the ability of immune cells to use fatty acids as fuel measurably slows disease progression in a mouse model of multiple sclerosis.

3 Sep 2011

Scientists identify several links between genetic variants and specific metabolic changes

Scientists at Helmholtz Zentrum Munich and LMU Munich, in cooperation with Wellcome Trust Sanger Institute and King's College London (KCL), have identified several associations between genetic variants and specific metabolic changes.

3 Sep 2011

Nature journal publishes Metabolon's genome wide association study

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced the publication of "Human Metabolic Individuality in Biomedical and Pharmaceutical Research" in the journal Nature.

3 Sep 2011

SAMHSA to unveil results of 2010 National Survey on Drug Use and Health

The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2010) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 8.

3 Sep 2011

Exercise triggers influential stem cells to become bone instead of fat

McMaster researchers have found one more reason to exercise: working out triggers influential stem cells to become bone instead of fat, improving overall health by boosting the body's capacity to make blood.

3 Sep 2011

AmerisourceBergen completes acquisition of Premier Source

AmerisourceBergen Corporation today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies.

2 Sep 2011

SuperGen is now Astex Pharmaceuticals

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it anticipates that it will begin operating under the name Astex Pharmaceuticals, Inc. on September 12, 2011.

2 Sep 2011

'Sustainable global pharmacovigilance' systems needed to monitor ARVs, other drugs

With more widespread access to antiretroviral (ARV) drugs comes a greater need to monitor and promote the safety and effectiveness of these essential medicines in the new environments, which are distinct from those of pre-market studies and the resource rich countries that have had ARV access for years.

2 Sep 2011

FDA may be allowed an extra 2 months to review new drugs

The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.

2 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.

31 Aug 2011

Study reveals how pharmaceutical managers can maximize the return on marketing investments

Research in Marketing Science by Professor Kamel Jedidi, John A. Howard Professor of Business, Marketing, Columbia Business School; Professor Oded Netzer, Philip H. Geier Jr. Associate Professor, Marketing, Columbia Business School; and Professor Ricardo Montoya, Department of Industrial Engineering, University of Chile, Santiago, Chile, reveals how pharmaceutical managers can maximize the return on marketing investments - by determining the physicians to target as well as when and how to target them.

31 Aug 2011

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria.

31 Aug 2011

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

Comprehensive review on non-drug interventions for treatment of high blood pressure

More and more, patients show up to appointments with hypertension expert John Bisognano, M.D., Ph.D. carrying bags full of "natural" products that they hope will help lower their blood pressure. And like most physicians, Bisognano doesn't always know if these products will do any good, or if they will cause any harm.

31 Aug 2011

Pharmaceuticals News and Research

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Teenagers use medicines frequently without receiving targeted information about risks and benefits

Researchers discover group of mutations involved in T-cell acute lymphoblastic leukemia

Berlin to market wide range of Acino Pharma's current and future products in Thailand

Study describes new class of anti-diabetic compound that targets unique molecular switch

Inhibiting the ability of immune cells to use fatty acids slows MS progression

Scientists identify several links between genetic variants and specific metabolic changes

Nature journal publishes Metabolon's genome wide association study

SAMHSA to unveil results of 2010 National Survey on Drug Use and Health

Exercise triggers influential stem cells to become bone instead of fat

AmerisourceBergen completes acquisition of Premier Source

SuperGen is now Astex Pharmaceuticals

'Sustainable global pharmacovigilance' systems needed to monitor ARVs, other drugs

FDA may be allowed an extra 2 months to review new drugs

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

Study reveals how pharmaceutical managers can maximize the return on marketing investments

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Comprehensive review on non-drug interventions for treatment of high blood pressure

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence